What is Insight Molecular Diagnostics Inc.'s earnings per share (EPS)?

Insight Molecular Diagnostics Inc. (IMDX) reported diluted earnings per share of -$1.65 for fiscal year 2025. EPS represents the portion of a company's net income allocated to each outstanding share of common stock and is widely used to evaluate profitability on a per-share basis.

Insight Molecular Diagnostics Inc. (IMDX) Financials

IMDX

Trailing 12 months to June 30, 2026

Revenue $1.7M -60.8% YoY

Net Income -$49.4M n/m YoY

EPS (Diluted) -$1.51 YoY not available

Free Cash Flow -$31.0M n/m YoY

Market Cap $92.6M as of Oct 23, 2026

Price / Sales 55.5x on $1.7M revenue, trailing 12 months to June 30, 2026

Price / Earnings n/m net loss, so no earnings multiple, trailing 12 months to June 30, 2026

Price / Book n/m negative shareholder equity, so no book multiple, Q2 FY2026

A multiple compares the market's price with a filed figure; it says what the market pays, not how the business is doing. The market capitalization is the vendor's as of Oct 23, 2026; every other figure is from the SEC filings on this page. Not financial advice.

Source SEC Filings (10-K/10-Q) Latest period Q2 FY2026, ended Jun 30, 2026 Reported Aug 10, 2026 Currency USD FYE December

Newest figures come from the 10-Q for Q2 FY2026, filed Aug 10, 2026. Each column of the statement tables below links to the filing it was taken from, and every filing is listed on the IMDX SEC filings page.

Insight Molecular Diagnostics Inc. (IMDX) reported $1.7M in revenue over the twelve months to Jun 30, 2026, down 60.8% from the prior twelve months. This page shows its income statement, balance sheet, cash flow statement, and key financial ratios. View 12 years of annual fundamentals and quarterly data, with year-over-year growth rates and compound annual growth rates (CAGR). All figures are derived from SEC filings (10-K and 10-Q reports).

Rhea AI IMDX FY2025 2026-10-24

Sales are scaling, but development-stage economics persist: R&D still dwarfs revenue and financing supports cash needs.

Revenue more than doubled from FY2024 to FY2025, rising 115.6%, while R&D rose 61.6%; growth is therefore occurring alongside continued development investment rather than operating self-funding. FY2025 operating cash flow was -$22.2M while financing cash flow was $28.1M, showing that external funding supplied more cash than operations generated.

Gross profit of $2.3M did not come close to covering an operating loss of $51.1M, so higher sales have not yet translated into operating leverage. R&D was $15.9M and SG&A was $17.0M, making the cost structure unusually large relative to the revenue base.

Liabilities of $57.2M exceeded assets of $25.8M, leaving negative equity of $31.5M and indicating that the balance sheet is funded more by obligations than residual shareholder capital. The current ratio was 1.3x versus 1.6x in FY2024, indicating less short-term cushion even as revenue expanded.

Financial Health Signals

Financial Health Score 43/100

Scored as: Emerging companies peer group

Scored against emerging companies for FY2025. Each of the six dimensions is a percentile rank within that peer group, and the overall is the average of the dimensions that can be computed. A high score means strong standing among peers, not absolute cross-industry strength. How this score is calculated →

Health score ≠ stock price. This rates the quality of Insight Molecular Diagnostics Inc.'s business: profitability, growth, balance sheet strength. It doesn't tell you whether the stock is a good buy at today's price. Not financial advice. Use it alongside valuation analysis and your own research.

Cash Runway

Insight Molecular Diagnostics Inc. held $11.6M in cash, cash equivalents and investments at the end of fiscal year 2025, and its operations used $22.2M of cash that year. Cash Runway ranks emerging companies on the size of that balance against the outflow behind it, and Insight Molecular Diagnostics Inc. scores 23/100 among other emerging companies.

Dilution

Insight Molecular Diagnostics Inc. had 32M shares outstanding at the end of fiscal year 2025. Dilution ranks emerging companies on how fast that count has grown over three years, where a slower rise is the better one, and Insight Molecular Diagnostics Inc. scores 12/100 among other emerging companies.

R&D Intensity

Insight Molecular Diagnostics Inc. spent $15.9M on research and development in fiscal year 2025, which was 28.8% of its operating costs that year. R&D Intensity ranks emerging companies on the share of operating costs that goes into research, and Insight Molecular Diagnostics Inc. scores 61/100 among other emerging companies.

Revenue Progress

Insight Molecular Diagnostics Inc. reported revenue of $4.1M in fiscal year 2025, against $1.9M in fiscal year 2024. Revenue Progress ranks emerging companies on the three-year path of that line, and Insight Molecular Diagnostics Inc. scores 82/100 among other emerging companies.

Burn Trend

Insight Molecular Diagnostics Inc.'s operations used $22.2M of cash in fiscal year 2025, against $20.7M used in fiscal year 2024. Burn Trend ranks emerging companies on which way that figure has moved over three years, and Insight Molecular Diagnostics Inc. scores 50/100 among other emerging companies.

Balance Sheet

Insight Molecular Diagnostics Inc.'s cash, cash equivalents and investments came to $11.6M at the end of fiscal year 2025, against $57.2M of total liabilities. Balance Sheet ranks emerging companies on that comparison, and Insight Molecular Diagnostics Inc. scores 27/100 among other emerging companies.

Altman Z-Score Distress

-27.06

Insight Molecular Diagnostics Inc. scores -27.06, below the 1.81 distress threshold. The score is pulled down most by an accumulated deficit of $400.8M against total assets of $25.8M. This indicates elevated financial distress risk and warrants close attention to liquidity and debt levels.

Distress-screening estimate for non-financial companies. Not computed for banks or insurers, where the Altman model does not apply.

Piotroski F-Score Partial

3/8

Insight Molecular Diagnostics Inc. passes 3 of 8 computable financial strength tests (1 of the nine could not be computed from available data). 1 of 4 profitability signals pass, no leverage/liquidity signals pass (rising debt, declining liquidity, or share dilution), both operating efficiency signals pass.

Earnings Quality No Cash Backing

N/A

Insight Molecular Diagnostics Inc. reported a net loss of $50.2M while operations used $22.2M of cash. With neither figure positive, the ratio between the two carries no quality signal.

Key Financial Metrics

Export CSV

Earnings & Revenue

Revenue

$239K

YoY-53.9%

QoQ+646.9%

5Y CAGR-34.8%

Insight Molecular Diagnostics Inc. generated $239K in revenue in Q2 2026. This represents a decrease of 53.9% from the same quarter a year earlier. Against the prior quarter it is up 646.9%.

EBITDA

-$10.7M

YoYn/m

QoQn/m

5Y CAGRn/m

Insight Molecular Diagnostics Inc.'s EBITDA was -$10.7M in Q2 2026, measuring earnings before interest, taxes, depreciation, and amortization. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Net Income

-$11.3M

YoYn/m

QoQn/m

5Y CAGRn/m

Insight Molecular Diagnostics Inc. reported a net loss of $11.3M in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

EPS (Diluted)

-$0.31

YoYn/m

QoQn/m

Insight Molecular Diagnostics Inc. earned -$0.31 per diluted share (EPS) in Q2 2026. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Balance Sheet

Free Cash Flow

-$10.0M

YoYn/m

QoQn/m

Insight Molecular Diagnostics Inc. recorded an outflow of $10.0M in free cash flow in Q2 2026, representing a cash shortfall after capex. The change from the same quarter a year earlier is not meaningful, because that figure was zero or negative. The change from the prior quarter is not meaningful, because that quarter’s figure was zero or negative.

Cash & Debt

$17.8M

YoY-26.9%

QoQ-37.0%

5Y CAGR-17.5%

10Y CAGR+16.1%

Insight Molecular Diagnostics Inc. held $17.8M in cash as of Q2 2026; no long-term debt figure is on record for that period.

Shares Outstanding

33M

YoY+14.3%

QoQ+1.3%

Insight Molecular Diagnostics Inc. had 33M shares outstanding in Q2 2026. This represents an increase of 14.3% from the same quarter a year earlier. Against the prior quarter it is up 1.3%.

Dividends Per Share

Not reported for Q2 2026.

Margins & Returns

Gross Margin

65.7%

YoY+0.4pp

QoQ+18.8pp

5Y change+32.2pp

Insight Molecular Diagnostics Inc.'s gross margin was 65.7% in Q2 2026, indicating the percentage of revenue retained after direct costs. This is up 0.4 percentage points from the same quarter a year earlier. Against the prior quarter it is up 18.8 percentage points.

Operating Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Net Margin

Not shown for Q2 2026: the reported ratio is below -100.0% of revenue, so it does not read as a share of revenue.

Return on Equity

Not reported for Q2 2026.

Capital Allocation

R&D Spending

$4.5M

YoY+37.2%

QoQ-9.4%

5Y CAGR+12.1%

Insight Molecular Diagnostics Inc. invested $4.5M in research and development in Q2 2026. This represents an increase of 37.2% from the same quarter a year earlier. Against the prior quarter it is down 9.4%.

Capital Expenditures

$779K

YoY+123.2%

QoQ+27.1%

Insight Molecular Diagnostics Inc. invested $779K in capex in Q2 2026, funding long-term assets and infrastructure. This represents an increase of 123.2% from the same quarter a year earlier. Against the prior quarter it is up 27.1%.

Share Buybacks

Not reported for Q2 2026.

IMDX Income Statement

Figures in USD, abbreviated K (thousand), M (million), B (billion), T (trillion). Negative values carry a minus sign and red type. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMDX quarterly income statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Revenue	$1.7M	$4.1M+115.6%	$1.9M+25.1%	$1.5M+56.9%	$958K-56.4%	$2.2M+80.8%	$1.2M	N/A	N/A	N/A	N/A	$0	N/A
Cost of Revenue	$856K	$1.8M+66.2%	$1.1M+5.1%	$1.0M+13.9%	$880K+26.3%	$697K-62.4%	$1.9M	N/A	N/A	N/A	N/A	N/A	N/A
Gross Profit	$807K	$2.3M+210.5%	$740K+79.2%	$413K+429.5%	$78K-94.5%	$1.4Mn/m	-$639K	N/A	N/A	N/A	N/A	N/A	N/A
R&D Expenses	$19.1M	$15.9M+61.6%	$9.8M+5.9%	$9.3M+27.3%	$7.3M+45.0%	$5.0M-48.6%	$9.8M+44.2%	$6.8M+4.3%	$6.5M-9.2%	$7.2M+26.4%	$5.7M+25.4%	$4.5M+14.3%	$4.0M
SG&A Expenses	$18.7M	$17.0M+20.0%	$14.1M+1.2%	$14.0M-39.3%	$23.0M+0.7%	$22.8M-1.9%	$23.3M+50.7%	$15.4M+77.8%	$8.7M-25.6%	$11.7M+113.7%	$5.5M+30.4%	$4.2M+314.5%	$1.0M
Operating Income	-$50.3M	-$51.1Mn/m	-$61.0Mn/m	-$25.1Mn/m	-$18.0Mn/m	-$53.7Mn/m	-$29.7Mn/m	-$22.2Mn/m	-$15.2Mn/m	-$18.8Mn/m	-$11.1Mn/m	-$8.7Mn/m	-$5.0M
EBITDA	N/A	-$48.9Mn/m	-$59.5Mn/m	-$23.5Mn/m	-$16.5Mn/m	-$52.9Mn/m	-$29.4Mn/m	-$21.9Mn/m	-$14.6Mn/m	-$18.3Mn/m	-$10.8Mn/m	-$8.4Mn/m	-$4.7M
Interest Expense	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$217Kn/m	$0-100.0%	$18Kn/m	$0
Income Tax	$0	$0n/m	$0n/m	$0	N/A	-$9.3Mn/m	-$1.3M	N/A	N/A	N/A	N/A	N/A	N/A
Net Income	-$49.4M	-$50.2Mn/m	-$60.7Mn/m	-$27.8Mn/m	-$72.9Mn/m	-$64.1Mn/m	-$29.9Mn/m	-$22.4Mn/m	-$15.8Mn/m	-$19.4Mn/m	-$11.2Mn/m	-$8.7Mn/m	-$5.0M
EPS (Basic)	N/A	-$1.65	-$4.66	-$3.75	-$13.25	-$0.72n/m	-$0.46n/m	-$0.44n/m	-$0.42n/m	-$0.64n/m	-$0.42n/m	-$0.42n/m	-$0.27
EPS (Diluted)	-$1.51	-$1.65	-$4.66	-$3.75	-$13.25	-$0.72n/m	-$0.46n/m	-$0.44n/m	-$0.42n/m	-$0.64n/m	-$0.42n/m	-$0.42n/m	-$0.27
Diluted Shares (Avg)	N/A	30M	13M	8M	6M	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Revenue	$239K-53.9%	$32K-98.5%	$1.1M-23.4%	$260K+126.1%	$518K+398.1%	$2.1M+1114.8%	$1.5M+373.2%	$115K-73.2%
Cost of Revenue	$82K-54.4%	$17K-97.9%	$636K-26.8%	$121K+181.4%	$180K+462.5%	$813K+645.9%	$869K+112.5%	$43K-73.0%
Gross Profit	$157K-53.6%	$15K-98.9%	$496K-16.6%	$139K+178.0%	$338K+576.0%	$1.3M+2844.4%	$595Kn/m	$50K-79.8%
R&D Expenses	$4.5M+37.2%	$5.0M+69.4%	$5.8M+158.3%	$3.9M+37.7%	$3.3M+33.3%	$2.9M+26.5%	$2.3M-11.4%	$2.8M+28.9%
SG&A Expenses	$4.8M+16.6%	$5.4M+24.8%	$4.6M+22.8%	$3.9M+9.0%	$4.1M+26.0%	$4.3M+22.8%	$3.8M+61.1%	$3.6M+12.8%
Operating Income	-$11.4Mn/m	-$4.4Mn/m	-$23.4Mn/m	-$11.0Mn/m	-$9.8Mn/m	-$6.8Mn/m	-$33.6Mn/m	-$13.5Mn/m
EBITDA	-$10.7Mn/m	-$3.8Mn/m	-$22.9Mn/m	-$10.5Mn/m	-$9.3Mn/m	-$6.3Mn/m	-$33.1Mn/m	-$13.2Mn/m
Income Tax	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0	$0
Net Income	-$11.3Mn/m	-$4.3Mn/m	-$23.0Mn/m	-$10.9Mn/m	-$9.7Mn/m	-$6.7Mn/m	-$33.5Mn/m	-$13.5Mn/m
EPS (Basic)	-$0.31n/m	-$0.12n/m	-$0.74	-$0.34	-$0.30	-$0.26	-$2.30	-$0.98
EPS (Diluted)	-$0.31n/m	-$0.12n/m	-$0.74	-$0.34	-$0.30	-$0.26	-$2.30	-$0.98
Diluted Shares (Avg)	37M+14.8%	35M+34.3%	N/A	32M	32M	26M	N/A	14M

Not reported in any period shown, so not listed: Interest Expense.

IMDX Balance Sheet

IMDX quarterly balance sheet

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Total Assets	$25.8M-26.6%	$35.1M-53.2%	$74.9M-25.2%	$100.1M-37.3%	$159.6M+187.9%	$55.4M+39.0%	$39.9M+318.8%	$9.5M-6.8%	$10.2M-29.3%	$14.4M+13.5%	$12.7M	N/A
Current Assets	$15.3M+30.2%	$11.8M+9.9%	$10.7M-58.1%	$25.5M-34.8%	$39.1M+324.3%	$9.2M-59.8%	$23.0M+165.6%	$8.6M+1.3%	$8.5M-32.8%	$12.7M+16.2%	$10.9M	N/A
Cash & Equivalents	$11.6M+34.1%	$8.6M-8.4%	$9.4M-52.8%	$20.0M-39.3%	$32.9M+361.3%	$7.1M-67.6%	$22.1M+174.7%	$8.0M+5.7%	$7.6M-25.3%	$10.2M+27.2%	$8.0M+3011.3%	$257K
Short-Term Investments	$0n/m	$0n/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	$0n/m	$0n/m	$0
Inventory	$446K+8.8%	$410K	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A
Accounts Receivable	$1.1M-30.1%	$1.6M+233.3%	$484K-75.9%	$2.0M+40.0%	$1.4M+607.9%	$203K	N/A	N/A	N/A	N/A	N/A	N/A
Long-Term Investments	$0n/m	$0n/m	$0	N/A	N/A	N/A	N/A	N/A	N/A	$0n/m	$0n/m	$0
Goodwill	N/A	N/A	N/A	N/A	$18.7M+103.4%	$9.2M0.0%	$9.2M	N/A	N/A	N/A	N/A	N/A
Total Liabilities	$57.2M+20.8%	$47.4M-3.9%	$49.3M-18.5%	$60.5M-35.9%	$94.3M+330.1%	$21.9M+143.2%	$9.0M+48.0%	$6.1M+4.9%	$5.8M+26.8%	$4.6M+98.1%	$2.3M	N/A
Current Liabilities	$12.1M+66.0%	$7.3M+1.1%	$7.2M-40.6%	$12.1M-14.3%	$14.1M+57.0%	$9.0M+102.6%	$4.4M-20.2%	$5.6M+24.9%	$4.5M+4.2%	$4.3M+84.7%	$2.3M	N/A
Non-Current Liabilities	$45.1M+12.6%	$40.1M-4.8%	$42.1M-13.0%	$48.4M-39.7%	$80.2M+520.0%	$12.9M+182.5%	$4.6M+757.9%	$534K-60.7%	$1.4M+338.4%	$310Kn/m	$0	N/A
Long-Term Debt	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	$1.9M	N/A	N/A	N/A
Total Equity	-$31.5Mn/m	-$12.3M-160.0%	$20.5M-40.3%	$34.3M-47.4%	$65.2M+94.8%	$33.5M+8.6%	$30.8M+800.9%	$3.4M-22.3%	$4.4M-55.4%	$9.9M-5.3%	$10.4Mn/m	-$1.1M
Retained Earnings	-$400.8Mn/m	-$350.5Mn/m	-$289.9Mn/m	-$260.7Mn/m	-$187.8Mn/m	-$123.7Mn/m	-$93.7Mn/m	-$71.3Mn/m	-$54.7Mn/m	-$35.3Mn/m	-$24.1M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Total Assets	$29.4M-41.7%	$40.4M-33.0%	$25.8M-26.6%	$43.9M-37.4%	$50.5M-32.4%	$60.4M-15.0%	$35.1M-53.2%	$70.2M-13.9%
Current Assets	$20.5M-23.5%	$30.5M-15.8%	$15.3M+30.2%	$21.4M+346.3%	$26.8M+169.3%	$36.3M+454.9%	$11.8M+9.9%	$4.8M-71.7%
Cash & Equivalents	$17.8M-26.9%	$28.2M-9.1%	$11.6M+34.1%	$18.7M+455.8%	$24.3M+162.4%	$31.0M+456.3%	$8.6M-8.4%	$3.4M-75.6%
Short-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Inventory	$207K-70.1%	$382K-16.8%	$446K+8.8%	$471K+103.0%	$693K	$459K	$410K	$232K
Accounts Receivable	$192K-62.5%	$157K-95.6%	$1.1M-30.1%	$258K+23.4%	$512K+502.4%	$3.5M+2098.8%	$1.6M+233.3%	$209K-64.8%
Long-Term Investments	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0n/m	$0
Total Liabilities	$50.7M+2.7%	$51.1M+1.9%	$57.2M+20.8%	$53.1M-12.2%	$49.4M-5.0%	$50.1M-7.2%	$47.4M-3.9%	$60.5M+54.7%
Current Liabilities	$10.3M+54.6%	$12.0M+24.0%	$12.1M+66.0%	$7.7M-15.7%	$6.7M-7.6%	$9.7M+16.3%	$7.3M+1.1%	$9.1M+13.2%
Non-Current Liabilities	$40.5M-5.4%	$39.1M-3.3%	$45.1M+12.6%	$45.5M-11.6%	$42.8M-4.6%	$40.5M-11.5%	$40.1M-4.8%	$51.4M+65.5%
Total Equity	-$21.3M-2039.8%	-$10.7M-204.6%	-$31.5Mn/m	-$9.2M-194.7%	$1.1M-95.2%	$10.2M-11.8%	-$12.3M-160.0%	$9.7M-73.1%
Retained Earnings	-$416.3Mn/m	-$405.1Mn/m	-$400.8Mn/m	-$377.8Mn/m	-$367.0Mn/m	-$357.2Mn/m	-$350.5Mn/m	-$317.0Mn/m

Not reported in any period shown, so not listed: Goodwill, Long-Term Debt.

IMDX Cash Flow Statement

IMDX quarterly cash flow statement

Metric	TTM	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Operating Cash Flow	-$27.1M	-$22.2Mn/m	-$20.7Mn/m	-$23.3Mn/m	-$45.6Mn/m	-$35.9Mn/m	-$26.0Mn/m	-$19.7Mn/m	-$11.6Mn/m	-$13.4Mn/m	-$7.5Mn/m	-$4.2Mn/m	-$1.2M
Depreciation & Amortization	N/A	$2.2M+40.5%	$1.6M-6.9%	$1.7M+9.9%	$1.5M+91.0%	$800K+155.6%	$313K-9.0%	$344K-38.5%	$559K-3.6%	$580K+49.9%	$387K+36.7%	$283K+0.7%	$281K
Stock-Based Compensation	N/A	$2.2M+26.6%	$1.8M-36.5%	$2.8M-72.5%	$10.0M+46.8%	$6.8M+35.0%	$5.1M+69.1%	$3.0M+102.5%	$1.5M-9.3%	$1.6M+76.8%	$922K-49.2%	$1.8M+470.8%	$318K
Capital Expenditures	$3.9M	$3.2M+517.2%	$516K+83.6%	$281K-93.5%	$4.3M+93.1%	$2.2M+83.1%	$1.2M+33.7%	$918K+2861.3%	$31K-65.9%	$91K-14.2%	$106K-78.8%	$500K+5455.6%	$9K
Free Cash Flow	-$31.0M	-$25.4Mn/m	-$21.2Mn/m	-$23.6Mn/m	-$49.9Mn/m	-$38.2Mn/m	-$27.2Mn/m	-$20.6Mn/m	-$11.7Mn/m	-$13.5Mn/m	-$7.6Mn/m	-$4.7Mn/m	-$1.2M
Investing Cash Flow	-$3.9M	-$3.2Mn/m	-$512Kn/m	-$932Kn/m	-$4.3Mn/m	-$14.0Mn/m	-$11.7Mn/m	-$12.4Mn/m	-$31K-103.7%	$843Kn/m	-$181K-157.5%	$315K	N/A
Financing Cash Flow	$23.8M	$28.1M+37.4%	$20.4M+67.6%	$12.2M-66.0%	$35.8M-54.3%	$78.4M+243.7%	$22.8M-52.4%	$47.9M+295.1%	$12.1M+21.5%	$10.0M+0.9%	$9.9M-15.2%	$11.7M	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Operating Cash Flow	-$9.3Mn/m	-$7.6Mn/m	-$5.5Mn/m	-$4.6Mn/m	-$6.2Mn/m	-$5.8Mn/m	-$5.4Mn/m	-$5.5Mn/m
Depreciation & Amortization	$665K+19.0%	$631K+28.5%	$563K0.0%	$584K+71.8%	$559K+71.5%	$491K+46.6%	$563K+44.0%	$340K-15.8%
Stock-Based Compensation	$661K+31.2%	$615K+30.0%	N/A	$521K+15.8%	$504K+30.6%	$473K+13.2%	N/A	$450K-26.0%
Capital Expenditures	$779K+123.2%	$613K+99.7%	$1.5M+591.1%	$1.1M+1106.9%	$349K+82.7%	$307K+1179.2%	$214K-18.9%	$87K
Free Cash Flow	-$10.0Mn/m	-$8.3Mn/m	-$7.0Mn/m	-$5.7Mn/m	-$6.5Mn/m	-$6.1Mn/m	-$5.6Mn/m	-$5.6M
Investing Cash Flow	-$779Kn/m	-$613Kn/m	-$1.5Mn/m	-$1.1Mn/m	-$349Kn/m	-$307Kn/m	-$210K-303.9%	-$87K-140.7%
Financing Cash Flow	-$564Kn/m	$24.7M-13.5%	-$252K-102.3%	-$120Kn/m	-$114K-101.2%	$28.6Mn/m	$10.8Mn/m	-$255Kn/m

Not reported in any period shown, so not listed: Dividends Paid, Share Buybacks.

IMDX Financial Ratios

Margins and returns are percentages; the remaining ratios are unitless multiples. Each change compares the year with the year before it, and each quarter with the same quarter a year earlier.

IMDX quarterly financial ratios

Metric	FY2510-K	FY2410-K	FY2310-K	FY2210-K	FY2110-K	FY2010-K	FY1910-K	FY1810-K	FY1710-K	FY1610-K	FY1510-K	FY1410-K
Gross Margin	56.7%+17.3pp	39.3%+11.9pp	27.5%+19.3pp	8.1%-56.5pp	64.6%+117.2pp	-52.5%	N/A	N/A	N/A	N/A	N/A	N/A
Operating Margin	-1260.8%	-3245.1%	-1672.4%	-1878.6%	-2444.3%	-2443.3%	N/A	N/A	N/A	N/A	N/A	N/A
Net Margin	-1238.5%	-3225.0%	-1848.4%	-7609.8%	-2916.2%	-2461.5%	N/A	N/A	N/A	N/A	N/A	N/A
Return on Equity	N/A	N/A	-135.7%+76.9pp	-212.6%-114.3pp	-98.3%-8.9pp	-89.4%-16.7pp	-72.7%+387.5pp	-460.2%-20.2pp	-440.0%-326.8pp	-113.2%-29.4pp	-83.9%	N/A
Return on Assets	-195.0%-22.1pp	-172.9%-135.8pp	-37.1%+35.8pp	-72.8%-32.7pp	-40.2%+13.8pp	-54.0%+2.2pp	-56.3%+109.3pp	-165.5%+24.1pp	-189.7%-112.3pp	-77.3%-8.7pp	-68.6%	N/A
Current Ratio	1.27-0.3x	1.62+0.1x	1.49-0.6x	2.11-0.7x	2.77+1.7x	1.03-4.1x	5.17+3.6x	1.55-0.4x	1.91-1.1x	2.97-1.8x	4.72	N/A
Debt-to-Equity	N/A	N/A	N/A	N/A	N/A	N/A	N/A	N/A	0.42	N/A	N/A	N/A
Liabilities-to-Equity	N/A	N/A	2.41+0.6x	1.76+0.3x	1.45+0.8x	0.66+0.4x	0.29-1.5x	1.78+0.5x	1.32+0.9x	0.46+0.2x	0.22	N/A
Asset Turnover	0.16+0.1x	0.050.0x	0.020.0x	0.010.0x	0.010.0x	0.02	N/A	N/A	N/A	N/A	0.00	N/A
FCF Margin	-625.6%	-1127.3%	-1570.6%	-5209.6%	-1737.4%	-2237.4%	N/A	N/A	N/A	N/A	N/A	N/A

Metric	Q2'2610-Q	Q1'2610-Q	Q4'2510-K	Q3'2510-Q	Q2'2510-Q	Q1'2510-Q	Q4'2410-K	Q3'2410-Q
Gross Margin	65.7%+0.4pp	46.9%-15.1pp	43.5%+3.5pp	53.5%+10.0pp	65.3%+17.2pp	62.0%+36.4pp	40.0%+77.3pp	43.5%-14.3pp
Operating Margin	-4770.7%	-13790.6%	-2057.5%	-4249.2%	-1900.0%	-318.0%	-2262.9%	-11752.2%
Net Margin	-4711.3%	-13406.3%	-2015.4%	-4174.6%	-1880.7%	-312.0%	-2255.1%	-11733.0%
Return on Equity	N/A	N/A	N/A	N/A	-887.3%-867.3pp	-65.3%+13.5pp	N/A	-138.9%-121.0pp
Return on Assets	-38.2%-19.0pp	-10.6%+0.4pp	-89.1%+6.4pp	-24.7%-5.5pp	-19.3%-13.2pp	-11.1%+1.8pp	-95.5%-74.2pp	-19.2%-11.3pp
Current Ratio	2.00-2.0x	2.54-1.2x	1.27-0.3x	2.79+2.3x	4.04+2.7x	3.75+3.0x	1.62+0.1x	0.53-1.6x
Liabilities-to-Equity	N/A	N/A	N/A	N/A	45.01+42.7x	4.91+0.2x	N/A	6.23+5.1x
Asset Turnover	0.010.0x	0.000.0x	0.040.0x	0.010.0x	0.010.0x	0.040.0x	0.040.0x	0.000.0x
FCF Margin	-4203.8%	-25787.5%	-616.7%	-2183.1%	-1259.3%	-287.5%	-374.5%	-4884.3%

Not reported in any period shown, so not listed: Debt-to-Equity.

Reported as filed but not readable as a share of revenue in the periods where the ratio runs further from zero than a revenue base allows; no change figure is given where either compared period is one of those: Operating Margin, Net Margin, FCF Margin.

Note: Shareholder equity is negative (-$31.5M), which causes the debt-to-equity, liabilities-to-equity and return on equity ratios to appear negative or not meaningful. This can occur from accumulated losses or large share buyback programs.

Similar Companies

Newest fiscal year on record for each company. The health score is the peer-relative Financial Health Score for that year; a dash means no score is published for it.

Company	Fiscal year	Revenue	Net income	Net margin	Market cap	Health score
Insight Molecular Diagnostics Inc. IMDX	FY2025	$4.1M	-$50.2M	N/A	$92.6M	43/100
Burning Rock Biotech Limited BNR	FY2025	$77.2M	-$7.9M	-10.3%	$124.7M	72/100
Prenetics Global Limited PRE	FY2025	$92.4M	-$40.0M	-43.3%	$338.6M	49/100
Biodesix, Inc. BDSX	FY2025	$88.5M	-$35.3M	-39.9%	$223.5M	52/100
MDxHealth SA MDXH	FY2025	$107.9M	-$33.5M	-31.1%	$17.6M	53/100

Where Insight Molecular Diagnostics Inc. Ranks

Frequently Asked Questions

What is Insight Molecular Diagnostics Inc.'s annual revenue?

Insight Molecular Diagnostics Inc. (IMDX) reported $4.1M in total revenue for fiscal year 2025. This represents a 115.6% change compared to the previous fiscal year. Revenue measures the total income earned from the company's primary business operations before any expenses are deducted.

How fast is Insight Molecular Diagnostics Inc.'s revenue growing?

Insight Molecular Diagnostics Inc. (IMDX) revenue grew by 115.6% year-over-year, from $1.9M to $4.1M in fiscal year 2025.

Is Insight Molecular Diagnostics Inc. profitable?

No, Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $49.4M over the trailing 12 months to June 30, 2026. In fiscal year 2025 it reported a net loss of $50.2M.

What is Insight Molecular Diagnostics Inc.'s EBITDA?

Insight Molecular Diagnostics Inc. (IMDX) had EBITDA of -$48.9M in fiscal year 2025, measuring earnings before interest, taxes, depreciation, and amortization.

What is Insight Molecular Diagnostics Inc.'s gross margin?

Insight Molecular Diagnostics Inc. (IMDX) had a gross margin of 56.7% in fiscal year 2025, indicating the percentage of revenue retained after direct costs of goods sold.

What is Insight Molecular Diagnostics Inc.'s free cash flow?

Insight Molecular Diagnostics Inc. (IMDX) recorded an outflow of $25.4M in free cash flow during fiscal year 2025. The change from the previous fiscal year is not meaningful, because that year’s figure was zero or negative. Free cash flow represents the cash a company generates after accounting for capital expenditures, and is widely used to assess financial flexibility and shareholder value.

What is Insight Molecular Diagnostics Inc.'s operating cash flow?

Insight Molecular Diagnostics Inc. (IMDX) recorded an outflow of $22.2M in operating cash flow during fiscal year 2025, representing cash used by core business activities.

What are Insight Molecular Diagnostics Inc.'s total assets?

Insight Molecular Diagnostics Inc. (IMDX) had $25.8M in total assets as of fiscal year 2025, including both current and long-term assets.

What are Insight Molecular Diagnostics Inc.'s capital expenditures?

Insight Molecular Diagnostics Inc. (IMDX) invested $3.2M in capital expenditures during fiscal year 2025, funding long-term assets and infrastructure.

How much does Insight Molecular Diagnostics Inc. spend on research and development?

Insight Molecular Diagnostics Inc. (IMDX) invested $15.9M in research and development during fiscal year 2025.

How many shares does Insight Molecular Diagnostics Inc. have outstanding?

Insight Molecular Diagnostics Inc. (IMDX) had 32M shares outstanding as of fiscal year 2025.

What is Insight Molecular Diagnostics Inc.'s current ratio?

Insight Molecular Diagnostics Inc. (IMDX) had a current ratio of 1.27 as of fiscal year 2025, which is considered adequate.

What is Insight Molecular Diagnostics Inc.'s return on assets (ROA)?

Insight Molecular Diagnostics Inc. (IMDX) had a return on assets of -195.0% for fiscal year 2025, measuring how efficiently the company uses its assets to generate profit.

What is Insight Molecular Diagnostics Inc.'s P/E ratio?

Insight Molecular Diagnostics Inc. (IMDX) has no price-to-earnings ratio at the moment: net loss, so no earnings multiple (trailing 12 months to June 30, 2026). The market capitalization is $92.6M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

What is Insight Molecular Diagnostics Inc.'s price-to-sales ratio?

Insight Molecular Diagnostics Inc. (IMDX) trades at 55.5x sales, its market capitalization divided by $1.7M revenue, trailing 12 months to June 30, 2026. The market capitalization is $92.6M as of Oct 23, 2026; a multiple compares that price with a filed figure and says nothing about the quality of the business.

How does Insight Molecular Diagnostics Inc.'s liquidity compare with its operating cash outflow?

At the end of fiscal year 2025, Insight Molecular Diagnostics Inc. (IMDX) held $11.6M in cash, cash equivalents and investments, and reported an operating cash outflow of $22.2M over that year. Dividing the one by the other, the reported balance equals about 6 months of the outflow reported that year. This is arithmetic over figures already filed, not a projection: it assumes nothing about future spending, financing or operations.

Why is Insight Molecular Diagnostics Inc.'s debt-to-equity ratio negative or not reported?

Insight Molecular Diagnostics Inc. (IMDX) has negative shareholder equity of -$31.5M as of fiscal year 2025, so no debt-to-equity or liabilities-to-equity ratio is reported: dividing debt by equity that is not positive produces a number that cannot be read as leverage. This can occur when accumulated losses exceed invested capital, or after large share buyback programs. Other solvency metrics like the current ratio or interest coverage may be more informative.

What is Insight Molecular Diagnostics Inc.'s Altman Z-Score?

Insight Molecular Diagnostics Inc. (IMDX) has an Altman Z-Score of -27.06, placing it in the Distress Zone (elevated bankruptcy risk). The Z-Score combines five financial ratios (working capital, retained earnings, EBIT, market capitalization, and revenue relative to total assets) to predict the likelihood of bankruptcy. Scores above 2.99 indicate financial safety while scores below 1.81 suggest financial distress. Learn more in our complete guide to financial health indicators.

What is Insight Molecular Diagnostics Inc.'s Piotroski F-Score?

Insight Molecular Diagnostics Inc. (IMDX) has a Piotroski F-Score of 3 out of 8 computable signals; 1 of the nine could not be computed from available data, so the full-scale strength rating is not shown. The F-Score evaluates nine binary signals across profitability (positive ROA, positive cash flow, improving ROA, earnings quality), leverage (decreasing debt, improving liquidity, no share dilution), and operating efficiency (improving gross margin, improving asset turnover). Scores of 7 to 9 indicate strong and improving fundamentals. Learn more in our complete guide to financial health indicators.

Are Insight Molecular Diagnostics Inc.'s earnings high quality?

Insight Molecular Diagnostics Inc. (IMDX) reported a net loss of $50.2M while operations used $22.2M of cash. With neither figure positive, the ratio between the two carries no quality signal. This ratio compares operating cash flow to net income. A ratio above 1.0x means the company generates more cash than its reported earnings, indicating sustainable, cash-backed profits. Ratios below 1.0x suggest earnings rely on accounting accruals rather than actual cash generation. Learn more in our complete guide to financial health indicators.

How financially healthy is Insight Molecular Diagnostics Inc.?

Insight Molecular Diagnostics Inc. (IMDX) scores 43 out of 100 on our Financial Health Score, indicating moderate standing within its emerging companies peer group. The score is the average of six dimensions (Cash Runway, Dilution, R&D Intensity, Revenue Progress, Burn Trend, Balance Sheet), each ranked as a percentile relative to companies in the same scoring family (banks against banks, REITs against REITs, and so on) rather than across all industries. It rates the quality of the business, not whether the stock is fairly priced, and is not financial advice. Learn more in our complete guide to financial health indicators.